3-(gamma-amino-beta-hydroxypropyl)-4-methyl-7-alkoxycarbonylalkoxy coumarins



United States Patent 496,167, Oct. 4, 1965. This application Sept. 3, 1968,

Ser. No. 757,098 Claims priority, application Germany, Oct. 17, 1964,

Int. (:1. c07a 29/20 US. Cl. 260-2943 6 Claims ABSTRACT OF THE DISCLOSURE The present invention relates to therapeutically valuable 3 ('y amino [3 hydroxypropyl)-4-methyl-7-hydroxycoumarin derivatives represented by the structural formula:

wherein R is a member selected from the group consisting of alkylamino radicals having 2-6 carbon atoms, alkoxyalkylamino radicals having 1-4 carbon atoms in the alkoxy and 34 carbon atoms in the alkyl group, dialkylamino radicals having 14 carbon atoms, allylamino, cyclohexylamino, piperidino, and morpholino; and R is a member selected from the group consisting of alkoxycarbonylalkyl radicals having 1-3 carbons in the alkyl and 1-6 carbons in the alkoxy group.

The present application is a continuation-in-part of United States Ser. No. 496,167, filed Oct. 4, 1965, now abandoned.

The 3-('y-amino-fi-hydroxypropyl)-4-methyl-7-hydroXycoumarin derivatives of the present invention are obtained 3,520,893 Patented July 21, 1970 by reacting 3-.('y-amino-fi-hydroxypropyl)-4-methyl-7-hydroxy-coumarins having the general formula om-omom-cm-m with compounds that are suitable for the introduction of the above designated residue R in particular halogeno compounds of the formula R -Hal, optionally in the presence of an acid-binding agent. The examples which follow illustrate specific methods of carrying out the reaction.

The 3-('y-amino-2-hydroxypropyl)-4-methyl-7-hydroxycoumarin derivatives of the present invention possess excellent vasodilatory action, in particular on the coronary vessels. In this respect, they are superior to the natural products papaverine and khelline.

To show the pharmacological superiority of the compounds under the present invention as compared with the 2,6 di (diethanolamino) 4,8 dipiperidinopyrimido(5,4 d)pyrimidine (dipyridamole), Well known as a commercial product having a good coronary vasodilatory action from Arzneimittelforschung 9, 39 to (1959), comparative tests with respect to the vasodilatory action were carried out in dogs according to the method disclosed by Eckenhoff, Hafkenschiel, and Landmesser in the American Journal of Physiology, 148 (1947) p. 582. The test preparations including known controls were injected intravenously into the narcotized animals. The coronary blood flow was measured by means of an automatic Bubble-Flow-Meter and the blood pressure was measured by means of an Anderson-Glass-Capsule Manometer. During the test period the animals were given artificial respiration. Under these test conditions the dilatation of the coronary artery, caused by the test substance, gives rise to a more rapid bubble fiow, whereas a constriction of the coronary vessels becomes evident from a retardation of the bubble flow, which is recorded by a kymograph.

As a comparative substance dipyridamole was similarly used in a standard dosage of 0.2 mg./ kg. As can be seen from the report by Kadatz in Arzneimittelforschung 9, 40 ,(1939), dosages higher than 0.2 mg./kg. of the Maximum increase Decrease 1n the Duration in the Duration Toxicity Dosage, coronary of the mean blood of the (LDso), n1g./l rg., flow in action in pressure action in Substance i.v. mouse 1.v. percent minutes in mm. Hg. minutes 3- ('y-pipcridino-fi-hydroxypropyl)-4rnethyl-7-ethoxy-carbonylmethoxycoumarin 0.145 1. 0 65 45 -5 45 3-(v-p peridino-B-hydroxypropyl)-4-methyl-7-hexy1oxycarbonylmethoxy 0. 022 2. 0 144 20 50 conmann 3-(' -piperidino-fl-hydroxypropyl)-4-methy1-7( -ethoxy arbonylpropoxy)- coumarin 2. 0 45 +5 45 3-( -diethylami hydroxypropyl)-t-methyl-7-ethoxy-carbonylmethoxy- (conlmallain1 "find. i) 4 fl 1 b hbnnmifi 0.12 2.0 118 65 5 (30 3- iet yamino-fly roxypropy -me y- -iso u oxy'car ony e oxycoumarin 0. 45 2. 0 63 40 +13 40 3-( -isopropylamino-fihydroxypropyl-4-methyl-7-ethoxycarbonylmethoxy- 0 18 f 1.0 90 -10 70 coumarin}. t.l. (i 11 Z h l t li .bunfifltil l 2 0 124 20 90 3- 'y- Z-buty amino -/3- y roxyplopy -me 1y e oxycar ony e oxycoumarin 0.1 2.0 104 45 1() 45 3-( -hexylaminofi-hydroxy opyl ethy thoxy-carbonylmethoxyunu m 37 5 74 30 3-( -cyc ohexy aminoy roxypropy -me y -e oxycar ony me oxycoumarin "D. .i1 l 7 "E .HUHHIYH 0.044 1.0 55 70 10 40 3- -mor holino- -h drox r0 -4-rnet -isobu oxycar ony e ioxyczzumai' inn I}; 0.16 2. 0 40 -3 2 3-('yplpGI'ldll'lWfi-IIYGIOXYDIODY -4-methy -7-methoxy-car onylme oxycoumarin "i1. .(1 .15 th -i 0. 13 2. 0 67 65 16 40 3-(v-dipropy1amino-(3- y roxypropy -me y coumarin (i .1). iilulunfii "bu-15h. 8 .0 97 70 +8 60 3-( -dimcthy1amino- 3hy roxypropy -4-me y7-e oxy-car ony e ioxyci urnarin .0 0. 04 2.0 25 40 -32 40 3- -dibut lamino-fiydroxyplopy -4=-me y-7-e oxy-car ony e oxyclumang 0. 032 2. 0 s2 40 -14 40 0.15 0.2 59 50 15 50 Comparative substance: dipyridamole The above results show that the novel derivatives of the 3-(- -amino-B-hydroxy-propy1) -4-methyl7-hydroxy-coumarin produce either a greater or a more prolonged coronary dilatation with the same efiect on the blood pressure or cause a lower efiect on the blood pressure mm the same coronary action,

as compared to the comparative compound dipyridamole.

4 Other 3 ('y-amino 13 hydroxypropyl)-4-methyl-7-hydroxy-coumarin derivatives having the formula OH2-CH(OH)CH2R1 were similarly prepared in which R and R of the above formula were represented by the following radicals:

coumarin derivatives, similar results being obtained with other derivatives not included in the table.

The following example will further illstrate how our invention may be carried out in practice, but the invenis not restricted to the example. All temperatures are degrees centigrade.

EXAMPLE 19.5 g. 3-('y-diethylamino-fl-hydroxypropyl)-4-methyl- 7-hydroxy-coumarin hydrochloride and 18 g. calcined potassium carbonate were stirred in 160 cc. dimethyl formamide at 70 for 2 hours. Then, while stirring, at 70 9 g. ethyl chloroacetate were allowed to slowly drip in. Stirring was then continued for 7 hours at 70. The reaction mixture was then filtered oif with suction and the filtrate evaporated to dryness in the vacuum. For further purification, the remaining raw product was dissolved in ethyl acetate and washed with diluted sodium hydroxide solution. By introducing hydrochloric acid gas into the dried ethyl acetate solution the reaction product was precipitated in the form of its hydrochloride. Yield: 13 g. (53.3% of the theoretical) 3-( -diethylaminofl-hydroxypropyl) 4 methyl-7-ethoxycarbonylmethoxycoumarin hydrochloride) having a melting point of 117.

The following are representative 3-(y-amino-fi-hydroxypropyl)-4-methyl-7-hydroxy-coumarin derivatives of the type covered by the above structural formula which have been found to possess excellent vasodi atory action, particularly on the coronary vessels:

3- ('y-piperidino-B-hydroxypropyl -4-methyl-7-ethoxycarbonyl-methoxy-coumarin;

3 ('y-piperidincyfl-hydroxypropyl -4-methyl-7-hexyloxycarbonyl-methoxy-coumarin;

3 ('y-piperidino-/3-hydroxypropyl -4-methyl-7- ('y-ethoxycarbonyl-propoxy) -coumarin;

3 ('y-diethylamino-fl-hydroxypropyl -4-methyl-7-ethoxycarbonyl-methoxy-coumarin;

3 'y-diethylaminofl-hydroxypropyl -4-methyl-7-isobutoxycarbonyl-methoxy-coumarin;

3 ('y-isopropyl amino -;3-hydroxyp ropyl -4-methyl-7- ethoxycarbonyl-methoxy-coumarin;

3- ['y- 2butylamino -;8-hydroxypropyl] -4-methoxy-7- ethoxycarbonyl methoxy-coumarin;

3 'y-hexylamino ,B-hydroxy pro pyl -4-methyl-7- ethoxycarbonyl-methoxy-coumarin;

3- 'y-cyclohexylamino-fl-hydroxypropyl -4-n1ethyl-7- ethoxycarbonyl-methoxy-coumarin 3- (y-morpholino-fl-hydroxypropyl -4-n1ethy1-7-isobutoxycarbonyl-methoxy-cournarin;

3-('y-piperidino-fi-hydroxypropyl) -4-1nethyl-7-methoxycarbonyl-rnethoxy-coumarin;

3-('y-dipropylamino-fl-hydroxypropyl)-4-methyl-7- ethoxycarbonyl-methoxy-cournarin;

3- -dirnethylarnino-B-hydroxypropyl-4-methyl-7-ethoxycarbonyl-methoxy-coumarin;

3 -dibutylamino-fi-hydroxypropyl -4-methyl-7-ethoxycarbonyl-methoxy-coumarin;

We claim: 1. A compound having the structural formula I CHzCH(OH)-CH2R1 B20 \O/O wherein R is a member selected from the group consisting of alkylamino radicals having 2-6 carbon atoms, alkoxyalkylamino radicals having 14 carbon atoms in the alkoxy and 3-4 carbon atoms in the alkyl group, dialkylamino radicals having 1-4 carbon atoms, allylamino, cyclohexylamino, piperidino and morpholino; and R is a member selected from the group consisting of alkoxycarbonyl, alkyl radicals having 13 carbons 6 in the alkyl and 1-6 carbons in the alkoxy group or the hydrochloride salt thereof.

2. 3 ('y piperidino [3 hydroxypropyl) 4-methyl-7- ethoxycarbonyl-methoxycoumarin according to claim 1 or the hydrochloride salt thereof.

3. 3-( diethylamino p hydroxypropyl)-4-methyl-7- ethoxycarbonyl-methoXy-coumarin according to claim 1 or the hydrochloride salt thereof.

4. 3 ('y-isopropylamino-;3-hydroxypropyl)-4-methyl-7- ethoxycarbonyl-methoxy-coumarin according to claim 1 or the hydrochloride salt thereof.

5. 3 ('y-cyclohexylamino-B-hydroxypropyl)-4-methyl- 7-ethoxycarbonyl-methoxy-coumarin according to claim 1 or the hydrochloride salt thereof.

6. 3- [v- (2'-butylamino -fl-hydroxypropyl] -4-rnethyl-7- ethoxycarbonyl-methoxy-coumarin according to claim 1 or the hydrochloride salt thereof.

No references cited.

ALEX MAZEL, Primary Examiner JOSE TOVAR, Assistant Examiner US. Cl. X.R. 

